918博天堂(中国)

    Pazopanib

    VOTRIENT®

    About VOTRIENT®

    1. Marketed by Novartis Pharmaceuticals Corporation (United States and European Union) and GlaxoSmithKline plc (Japan)
    2. Selective multi-targeted receptor tyrosine kinase inhibitor
    3. Treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma

    Approvals

    1. First E.U. approval: June 14, 2010
    2. First U.S. approval: October 19, 2009

    Constraint date forecast:

    1. Patent expiry: 2023 (United States)
    2. SPC expiries: 2025 (European Union)
    3. Patent expiry: 2027 (Japan)

    The future of the generics landscape

    From innovation to bottom line

    Access our global intelligence, advanced analytics and global team of experts.

    Contact our team